Researchers discovered that the most common form of non-Hodgkin lymphoma is actually two distinct diseases
In 2000, researchers discovered that the most common form of non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma, is…
In 2000, researchers discovered that the most common form of non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma, is…
On Jan. 10, 2012, the Norris Foundation made a $15 million commitment toward construction of the Harlyne J….
In 2000, Stanford researchers led by Ash Alizadeh announced they had used gene expression profiling to identify two…
In 2000, Georgetown Lombardi Comprehensive Cancer Center, was founded when the Georgetown University Medical Center authorized the establishment…
On Apr. 26, 2000, the Jon M. Huntsman pledged $125 million to fund cancer research and construct the…
In 2000, the Fred Hutchinson Business Alliance announced that the E. Donnall Thomas Medal of Achievement was awarded…
On Dec. 29, 1999, the U.S. Food and Drug Administration (FDA) approved Bexarotene (Targretin) to treat cutaneous T-cell…
On Dec. 8, 1999, the National Cancer Institute published the Atlas of Cancer Mortality, 1950-94, showing the geographic…
On Dec. 2, 1999, Alvin and Ruth Siteman donated $35 million to establish the Alvin J. Siteman Cancer…
On Nov. 19, 1999, National Colorectal Cancer Awareness Month was established with a declaration by the U.S. Senate,…
On Feb. 8, 1999, The Pancreatic Cancer Action Network was founded by Paula Kim, Terry Lierman and Pamela…
In Jan. 1999, the Carbone Cancer Center and McArdle Laboratories merged and began to function as a single…
In 1999, The Indiana University (IU) Cancer Center became an National Cancer Institute (NCI)-designated cancer center. Its mission…
In 1999, the Hudson-Webber Cancer Research Center opened to serve as a ‘translational’ research facility, bridging the gaps…
In 1999, Timothy J. Eberlein, MD was named director of the Alvin J. Siteman Cancer Center. As director…
In 1999, Siteman Cancer Center investigators joined the STAR (Study of Tamoxifen and Raloxifene) trial for breast cancer…
In 1999, Washington University – St. Louis radiation oncologists were instrumental in developing the world’s first big bore…
In 1999, the Eppley Cancer Center became a National Cancer Institute (NCI) designated cancer center. NCI grant funding…
In 1999, the Vancouver Prostate Centre received a $20 million donation by Vancouver businessman Jim Pattison, the largest…
In 1999, University of California at San Francisco Cancer Research Institute received NCI Comprehensive Cancer Center designation. The…
In 1999, the Fred Hutchinson Business Alliance announced that the 1999 E. Donnall Thomas Medal of Achievement would…
In 1999, Trubion Pharmaceutical was founded in Seattle as a spin-off from the Pacific Northwest Diabetes Research Institute,…
On Dec. 22, 1998, Washington University – St. Louis researcher Jeffrey I. Gordon, MD and colleagues developed a…
On Sept. 25, 1998, the U.S. Food and Drug Administration (FDA) approved the monoclonal antibody Herceptin (Trastuzumab) for…
On Sept. 14, 1998, researchers from the Breast Cancer Prevention Trial (BCPT) published a full report and update…
On Jul. 29, 1998, the Stamp Out Breast Cancer stamp was first issued. The driving force behind the…
On Jun. 16, 1998, University of Washington Medicine, Fred Hutchinson Cancer Research Center and Seattle Children’s announced the…
On April 30, 1998, the Food and Drug Administration (FDA) approved the Genentech’s drug Xeloda (capecitabine) for the…
On Jan. 13, 1998, Seattle Genetics (Seagen) was founded in Bothell as a biotechnology company focused on developing…
In 1998, The University of Minnesota Cancer Center, which was founded in 1991, was renamed the Masonic Cancer…